GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors.
Solid Tumor
DRUG: GX-I7|DRUG: Cyclophosphamide
Incidence of DLT, Incidence of nature of DLTs, within cycle 1(28days)|Incidence and characteristics of AE, Incidence, nature and severity of adverse events graded according to NCI CTCAEv4.03, up to 24 months|ORR, ORR defined as complete response (CR) or partial response (PR) per RECIST v1.1, up to 6 months
Incidence of ADAs, Incidence of anti-drug antibodies (ADAs) during the study, up to 24 months|concentration of GX-I7, Serum concentration of GX-I7 at specified timepoints for the Area under the concentration time-curve (AUC), up to cycle 3 day 1(approximately 8 weeks)
This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors.

This is 4 dose levels and increase dose level after confirm DLT of the previous dose.